
Opinion|Videos|January 17, 2025
Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
Author(s)Hadar Lev-Tov, MD
Panelist discusses how delayed medical diagnosis causes significant economic burden through increased treatment costs, prolonged health care interventions, reduced patient productivity, and higher health care system expenses. Economic mitigation strategies include implementing early screening programs, improving diagnostic technologies, enhancing medical training, and developing robust health care infrastructure that prioritizes timely patient assessment and intervention.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the economic implications of delayed diagnosis on both patients and health systems, and how can these be mitigated?
Advertisement
Related to this article

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
5



